Long-Acting ART: What You Need to Know
This month, pharmacist Gary Meyers discussed intramuscular cabotegravir-rilpivirine (CAB-RPV) as the first approved long-acting antiretroviral treatment regimen. He discussed who is eligible and why long-acting therapy may help patients. He also explained why usage has been limited thus far due to clinical factors, insurance coverage, and logistical barriers.
Objectives:
By the end of this presentation, attendees were able to:
- Understand more about long-acting antiretroviral therapy;
- Know who is eligible for long-acting therapy;
- What will be different for patients switching to long-acting ARV;
- Know dosing recommendations and appropriate schedules for long-acting antiretroviral therapy; and,
- Understand the appropriate steps if a patient misses a dose.
Contact Darci Bultje for the recording.
